Journal Basic Info
- Colorectal Cancer
- Cervical Cancer
- Neoadjuvant Therapy
- Bladder Cancer
- Targeted Therapy
- Surgical Oncology
Citation: Clin Oncol. 2019;4(1):1593.DOI: 10.25107/2474-1663.1593
Lauren Chen and Mithil Soni
Department of Biological Science, University of South Carolina, USA
MicroRNAs (microRNAs) are short sequences of RNA (about 22 nucleotides) that are involved in the regulation of gene expression. Previous studies have suggested that a number of microRNAs are recognized as new biomarkers for cancers. The aim of this study is to identify specific microRNAs in serum, which may serve as potential diagnostic and prognostic biomarkers and therapeutic targets for breast cancer. Quantitative real-time PCR (qRT-PCR) array analyses of microRNAs in sera from four pairs of recurrent and non-recurrent breast cancer patients were performed. Those differentially expressed microRNAs were verified in serum samples from 42 breast cancer patients. The prognostic values of the selected microRNAs were statistically analyzed, determined by the correlation between microRNA expression and tumor parameters. High serum levels of miR-134 and miR-483-5p were found to be associated with some aggressive tumor behaviors. Kaplan-Meier analysis of four up regulated microRNAs (miR-134, miR-483-5p, miR-493-3p and miR-139-3p) indicated that serum level of miR-134 can predict tumor recurrence in breast cancer patients after primary treatment. Identification of new blood biomarkers for prediction of recurrence may have a significant implication for breast cancer follow-up care and treatment.
microRNA; Biomarker; Recurrence; Breast cancer
Cite the Article:
Chen L, Soni M. Identification of MicroRNAs as New Blood Biomarkers to Predict Breast Cancer Recurrence. Clin Oncol. 2019; 4: 1593.